Bryan F. Cox

Dr. Cox is currently President of CoPharm Global Consulting, a boutique consultancy focused on providing guidance for biotechs and due diligence teams as they determine the best path forward from early discovery to first-in-man studies. Three of those projects have resulted in compounds obtaining U.S. FDA Regulatory Approval: delafloxacin (Baxalta® - NDA), amantadine (Gocovri® - 505b2), and angiotensin II (Giapreza® - NDA/505b2 hybrid).

Prior to CoPharm Global, he was Director of Integrative Pharmacology at Abbott/Abbvie - responsible for both lead optimization and IND-enabling studies. In parallel, he served as Head of Renal Discovery.

He has (co-) authored/approved over 250 documents for Regulatory submission and participated in the advancement of over 60 compounds to Phase 1 clinical trials. Dr. Cox has published more than 100 papers in peer-reviewed journals and has twice been elected to Council for the American Society of Pharmacology and Experimental Therapeutics.

Prior to joining Abbott, Dr. Cox was with Rhone Poulenc Rorer. He received his PhD in Pharmacology from the University of Iowa and is currently an adjunct Professor of Pharmacology at the University of Iowa, College of Medicine.